Skip to content
Menu

HC Wainwright & Co. Downgrades NeuroSense Therapeutics to Neutral

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsDowngrades

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Lander Egaña Gorroño downgrades NeuroSense Therapeutics (NASDAQ:NRSN) from Buy to Neutral.

HC Wainwright & Co. analyst Lander Egaña Gorroño downgrades NeuroSense Therapeutics (NASDAQ:NRSN) from Buy to Neutral.

Read at benzinga.com